X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
neurosciences (128) 128
animals (126) 126
male (69) 69
rats (68) 68
basal ganglia (67) 67
index medicus (46) 46
humans (40) 40
striatal neurons (40) 40
rats, sprague-dawley (38) 38
neurons - metabolism (37) 37
female (35) 35
parkinson's disease (35) 35
disease models, animal (34) 34
parkinsons-disease (32) 32
striatum (32) 32
gene-expression (31) 31
in situ hybridization (31) 31
mice (24) 24
rna, messenger - metabolism (24) 24
brain (23) 23
dopamine (23) 23
clinical neurology (22) 22
immunohistochemistry (22) 22
neurology (22) 22
corpus striatum - metabolism (21) 21
messenger-rna (21) 21
striatal projection neurons (21) 21
dopamine - metabolism (20) 20
enkephalins - genetics (19) 19
gene expression (19) 19
messenger-rna levels (19) 19
brain - metabolism (17) 17
huntington disease - genetics (17) 17
motor activity - drug effects (17) 17
substantia-nigra (17) 17
enkephalin (16) 16
huntington disease - pathology (16) 16
neurons - drug effects (16) 16
pharmacology & pharmacy (16) 16
protein precursors - genetics (16) 16
article (15) 15
biochemistry & molecular biology (15) 15
enkephalins - metabolism (15) 15
rat (15) 15
brain - drug effects (14) 14
huntington disease - metabolism (14) 14
levodopa - adverse effects (14) 14
striatal preproenkephalin (14) 14
time factors (14) 14
behavior, animal - drug effects (13) 13
corpus striatum - drug effects (13) 13
glutamate (13) 13
huntington's disease (13) 13
messenger-rna expression (13) 13
neostriatum (13) 13
neostriatum - metabolism (13) 13
nervous system (13) 13
neurons (13) 13
rats, wistar (13) 13
rna, messenger - biosynthesis (13) 13
dyskinesia (12) 12
neurons - pathology (12) 12
preproenkephalin (12) 12
psychiatry (12) 12
rat striatum (12) 12
tyrosine 3-monooxygenase - metabolism (12) 12
central-nervous-system (11) 11
corpus striatum - cytology (11) 11
corpus striatum - pathology (11) 11
dose-response relationship, drug (11) 11
dyskinesia, drug-induced - physiopathology (11) 11
levodopa-induced dyskinesia (11) 11
levodopa-induced dyskinesias (11) 11
mice, transgenic (11) 11
movement disorders (11) 11
mutant huntingtin (11) 11
nerve tissue proteins - genetics (11) 11
neurons - cytology (11) 11
protein precursors - metabolism (11) 11
reward (11) 11
rodents (11) 11
substance-p (11) 11
substantia nigra - drug effects (11) 11
6-hydroxydopamine (10) 10
antiparkinson agents - adverse effects (10) 10
brain - pathology (10) 10
dynorphin (10) 10
gene expression regulation - drug effects (10) 10
insitu hybridization (10) 10
levodopa (10) 10
oxidopamine (10) 10
parkinson disease - drug therapy (10) 10
substance p (10) 10
substantia nigra (10) 10
ventral tegmental area (10) 10
basal ganglia - metabolism (9) 9
dopamine - physiology (9) 9
expression (9) 9
gene expression - drug effects (9) 9
globus pallidus - metabolism (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2013, Volume 62, pp. 307 - 312
Journal Article
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 09/2001, Volume 21, Issue 17, pp. 6853 - 6861
The concept of a threshold of dopamine (DA) depletion for onset of Parkinson's disease symptoms, although widely accepted, has, to date, not been determined... 
Striatum | Threshold for symptom appearance | Compensatory mechanisms | Substantia nigra | dopaminergic receptor upregulation | Early D | Dopaminergic homeostasis | substantia nigra | dopaminergic homeostasis | compensatory mechanisms | SUBSTANTIA-NIGRA | DOPAMINE TRANSPORTER | DIFFERENTIAL REGULATION | NEUROSCIENCES | MESSENGER-RNA LEVELS | MPTP-INDUCED PARKINSONISM | MONKEY MACACA-FASCICULARIS | striatum | early D-2 dopaminergic receptor upregulation | RECEPTOR SUPERSENSITIVITY | HUMAN-BRAIN | threshold for symptom appearance | STRIATAL PREPROENKEPHALIN | Substantia Nigra - physiopathology | Neurons - pathology | Tyrosine 3-Monooxygenase - metabolism | Substantia Nigra - pathology | Cell Count | Macaca fascicularis | Motor Activity - drug effects | Receptors, Dopamine D2 - metabolism | Parkinson Disease, Secondary - pathology | Behavior, Animal - drug effects | Female | Neurons - metabolism | Membrane Glycoproteins | Parkinson Disease, Secondary - chemically induced | Carrier Proteins - analysis | Corpus Striatum - pathology | Dopamine - analysis | Dopamine Plasma Membrane Transport Proteins | Disease Models, Animal | Homovanillic Acid - analysis | Binding, Competitive | Caudate Nucleus - chemistry | Corpus Striatum - physiopathology | Drug Administration Schedule | Putamen - chemistry | Nerve Tissue Proteins | 3,4-Dihydroxyphenylacetic Acid - analysis | Disease Progression | Autoradiography | Substantia Nigra - drug effects | Animals | Carrier Proteins - metabolism | Membrane Transport Proteins | Parkinson Disease, Secondary - physiopathology | Corpus Striatum - drug effects | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Journal Article
Neuropharmacology, ISSN 0028-3908, 04/2014, Volume 79, pp. 688 - 706
Brain glutamate overactivity is well documented in Parkinson's disease (PD) and antiglutamatergic drugs decrease L-3,4-dihydroxyphenylalanine (l-DOPA)-induced... 
Preproenkephalin | Akt/GSK3 | ERK1/2 | MPEP | Dopamine receptor | Preprodynorphin | METABOTROPIC GLUTAMATE RECEPTORS | NEUROSCIENCES | MESSENGER-RNA LEVELS | HYBRIDIZATION HISTOCHEMICAL ANALYSIS | LEVODOPA-INDUCED DYSKINESIA | INDUCED MOTOR COMPLICATIONS | MPTP-TREATED MONKEYS | TARGETING GLUTAMATE | GENE-EXPRESSION | PHARMACOLOGY & PHARMACY | STRIATAL NEURONS | MOLECULAR-MECHANISMS | MAP Kinase Signaling System - physiology | Antiparkinson Agents - pharmacology | Enkephalins - metabolism | Parkinsonian Disorders - complications | Basal Ganglia - metabolism | Macaca fascicularis | Glycogen Synthase Kinase 3 beta | RNA, Messenger - metabolism | Receptors, Dopamine D2 - metabolism | Corpus Striatum - metabolism | Receptors, Dopamine D1 - metabolism | Parkinsonian Disorders - metabolism | Dyskinesia, Drug-Induced - drug therapy | Parkinsonian Disorders - drug therapy | Female | Dynorphins - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Receptors, Dopamine D1 - antagonists & inhibitors | Levodopa - pharmacology | Receptor, Metabotropic Glutamate 5 - antagonists & inhibitors | Excitatory Amino Acid Antagonists - pharmacology | Glycogen Synthase Kinase 3 - metabolism | Receptor, Metabotropic Glutamate 5 - metabolism | Antiparkinson Agents - adverse effects | Protein Precursors - metabolism | Animals | MAP Kinase Signaling System - drug effects | Dopamine Antagonists - pharmacology | Levodopa - adverse effects | Corpus Striatum - drug effects | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Pyridines - pharmacology | Dyskinesia, Drug-Induced - metabolism | Dopamine D2 Receptor Antagonists | Basal Ganglia - drug effects | Proteins | Evaluation | Brain | Pyridine | RNA | Phenols | Neuropeptides | Monkeys | Glutamate | Dopa | Dopamine receptors
Journal Article